

Montenegro

Tuberculosis profile

Population 2016

<1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	0.19 (0.17–0.2)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0 (0–0.01)
Incidence (includes HIV+TB)	0.1 (0.086–0.12)	16 (14–18)
Incidence (HIV+TB only)	0 (0–0)	0.03 (0.02–0.03)
Incidence (MDR/RR-TB)**	0 (0–0)	0 (0–0)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	<0.01 (<0.01–<0.01)	0.029 (0.024–0.033)	0.034 (0.029–0.039)
Males	<0.01 (<0.01–<0.01)	0.061 (0.051–0.07)	0.066 (0.056–0.076)
Total	0.011 (<0.01–0.012)	0.089 (0.076–0.1)	0.1 (0.086–0.12)

TB case notifications, 2016	
Total cases notified	87
Total new and relapse	87
- % tested with rapid diagnostics at time of diagnosis	29%
- % with known HIV status	69%
- % pulmonary	89%
- % bacteriologically confirmed among pulmonary	75%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.01 (0.01–0.01)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			0 (0–0)
Estimated % of TB cases with MDR/RR-TB	0% (0–7.1)	0% (0–41)	
% notified tested for rifampicin resistance	68%	50%	57
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 1	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 1	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	93%	80
Previously treated cases, excluding relapse, registered in 2015		0
HIV-positive TB cases registered in 2015		0
MDR/RR-TB cases started on second-line treatment in 2014	0%	2
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	<1
Funding source: 100% domestic, 0% international, 0% unfunded	

* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

